follow-up (p = 0.03). Acceptance of the PSP decreased in pts with higher degree of education, although not statistically significantly (82.1% vs 58.5%p = 0.10). Satisfaction with the program was perceived as high in 78% of the participants with a median VAS of 7 (IQR 5-9). Quality of life and limitation in daily activities, significantly improved in the A-PSP group (p = 0.007), but not in the R-PSP (p = 0.26) and CM groups (p = 0.12) at 6 months of follow-up. No improvement in WPAI was observed in any of the groups. Conclusions: Overall, PSP was well accepted by the participants, with the highest acceptance in pts with low grade of education. PSP could improve adherence over time and quality of life in IBD pts, especially in those with poor adherence to therapy, by increasing patients' confidence/education and perception of support and care.
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Pharmacokinetics of golimumab in patients with moderate-to-severe ulcerative colitis S. Berends* 1 , A. Strik 2 , P. van Egmond 1 , H. Brandse 2 , R. Mathôt 1 , G. D'Haens 2 , M. Löwenberg 2 1 Academic Medical Centre (AMC), Hospital Pharmacy, Amsterdam, Netherlands, 2 Academic Medical Centre (AMC), Gastroenterology, Amsterdam, Netherlands Background: Golimumab is a new treatment option for patients with moderate-to-severe ulcerative colitis (UC). However, after an initial response a substantial proportion of patients loses response over time. This may be due to the development of antibodies to golimumab (ATG) or insufficient target engagement. Moreover, therapeutic antibodies are lost via degradation by metalloproteinases and enteric protein shedding. Therefore, we investigated the pharmacokinetics (PK) of golimumab in UC patients to further understand the dose-response relationship of this treatment. Methods: In this ongoing prospective observational trial, patients with moderate-to-severe UC received induction treatment of subcutaneous golimumab (200 mg [day 1] and 100 mg [day 14]), followed by maintenance treatment with 50 or 100 mg every 4 weeks, in patients with a body weight of less or more than 80 kg, respectively. Serum golimumab concentrations, CRP, albumin, and ATG levels were measured and SCCAI was scored at standard time points. Endoscopy was performed at baseline and after induction treatment at week 8 using the Mayo endoscopic sub-score. PK analysis was performed using nonlinear mixed effects modelling (NONMEM). Results: Preliminary data from 6 patients during induction treatment were available. Median age at start was 44 (interquartile range [IQR], 35-57 years), and median baseline parameters were CRP 2.7 mg/L [0.48-17 mg/L], albumin 45 g/L [43-47 g/L], SCCAI 10 [6.5-12], and endoscopic Mayo score 2.0 [2.0-2.3]. Concentration-versustime profiles were best described by a 1-compartment PK model with first-order absorption and elimination. Mean values (plus between subject variability) for clearance, volume of distribution and absorption rate constant for a patient with CRP of 2.7 mg/L were 0.74 L/ day (42%), 13.8 L (35%), and 0.511 L/day, respectively. CRP was significantly correlated with clearance, which increased with 5.2% (95% CI 1.4-9.0%) per mg/L CRP rise (p < 0.05). Median outcome patient parameters after induction treatment at week 8 were CRP 2.2 mg/L (1.1-15 mg/L), SCCAI 8.0 (4.5-12) and Mayo score 2.0 (1.0-2.5). None of the patients developed ATG. Conclusions: This study demonstrates an association between inflammation (CRP) and clearance of golimumab. This may indicate that clearance is dependent on the severity of inflammation. Upon inclusion of more patients, the developed population PK model will be extended to determine the factors influencing PK. Further, faecal concentrations and the relationship between exposure and clinical/ endoscopic outcome will be determined. Background: IMPACT III is a validated, disease-specific healthrelated quality of life (HRQoL) questionnaire for children with inflammatory bowel disease. The 35-item IMPACT III questionnaire has been restructured to 4 domains for improved construct validity and reliability: emotional functioning, social functioning, body image, and well-being. 1 Using the re-categorised tool, we assessed the effect of adalimumab (ADA) on social and emotional function and examined the consistency of changes in individual questions within these domains in patients (pts) enrolled in the IMAgINE 1 trial. 2 Methods: IMAgINE 1 was a 52-week (wk) trial of ADA that enrolled 6-17 year (yr)-old pts with moderate-to-severe CD (baseline [BL] PCDAI >30) who failed or were intolerant to conventional therapy. 2 Pts experiencing disease flare/non-response could move to blinded weekly (ewk) ADA after wk 12, followed by open-label (OL) ewk ADA for continued flare/non-response. The IMPACT III questionnaire was administered to pts ≥10 yr at BL; the range for each individual question is 0 to 100; higher scores represent better quality of life (QoL). Total IMPACT III scores were normalised (sum of responses divided by number of questions answered; scale 0 = poor to 100 = best), each domain score was normalised (sum of responses for each question within domain divided by total number of questions answered; scale 0 to 100). Change from BL at wk 12, 26, and 52 in the score for each domain and in individual IMPACT III questions were reported. Last observation carried forward (LOCF) was used to account for missing data (post-BL), pts who discontinued, or who moved to OL ewk ADA. Results: In total, 172 pts in IMAgINE 1 were analysed (54.7% male; median PCDAI 40; median CRP 1.2 mg/dL; and mean IMPACT III total score 57 at BL). Mean emotional and social domain scores at BL were 54 and 72, respectively. Statistically significant improvements were observed for both domain scores and some individual questions in each domain as early as wk 12, and were sustained to wk 52 (Table 1) . Conclusions: ADA treatment was associated with early and substantial HRQoL improvements in children with CD, as indicated by statistically significant mean increases in emotional and social functioning domain scores and in most individual questions in each domain.
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Assessment of IMPACT III emotional and social functioning domain scores in adalimumabtreated paediatric patients with Crohn's disease
